A research team has discovered a metabolic vulnerability in multiple types of cancer cells that bear a common genetic mutation affecting cellular machines called spliceosomes.
Read moreInvestigators analyzed 40 years of cancer burden data and examined patterns of incidence and mortality for various cancers, finding examples for which incidence and mortality moved in concert and examples where discordance in incidence and mortality indicate that overdiagnosis may be at play.
Read moreTwo very different mutations have been identified as unexpected partners in crime for causing the blood cancer acute myeloid leukemia (AML). Expert analysis from CSHL helped reveal how this deadly duo is far more common in AML than thought.
Read moreA study in mice showed that reducing a particular hormone signal keeps the cancer from growing and spreading.
Read moreA new study finds that a form of immunotherapy used to treat the blood cancer leukemia may be effective in treating other kinds of cancer as well.
Read moreA decades-long decline in the breast cancer death rate continues, but has begun to slow in recent years.
Read moreScientists have found a common, new source of tumor mutations that could offer three levels of therapy with a cancer vaccine: 1) a broadly protective, or pan-cancer vaccine 2) cancer-type specific vaccines (e.g. breast vs. pancreatic), 3) personalized cancer vaccines based on mutations unique to an individual.
Read moreFor the first time ever, a professor has observed a crystallized iron product called hemozoin being made in mammals, with widespread implications for future research and treatment of blood disorders. Findings could be used to treat sickle cell disease and malaria patients, while opening up diverse research avenues across immunology, parasitology, neuroscience, microbiology, and even urology.
Read moreIn the prospective TAILORx trial, 93% of women with hormone-sensitive, HER2-negative, axillary node-negative breast cancer and a high Recurrence Score 26-100 were estimated to be cancer-free at five years. This outcome was much better than expected with endocrine therapy alone. The finding adds to limited data on outcomes with a high RS of 26-100, treated with taxane and/or anthracycline-containing chemotherapy plus endocrine therapy. It adds to the body of evidence supporting use of the RS.
Read morePatients with mesothelioma may gain similar benefit from immunotherapy as chemotherapy, and good responders may provide important clues to novel treatment for the thousands of new cases each year. New data highlight the need to understand the biological mechanisms whereby mesothelioma, which is incurable, adapts to immunotherapy in some patients but not in others, resulting in variations in treatment response.
Read more